In a bid to widen access to insulin in primarily low-income nations in Africa, Eli Lilly has agreed to sell active pharmaceutical ingredients and transfer technology to an Egyptian company that expects to supply the life-saving diabetes treatment to as many as 1 million people by 2030.
The 10-year agreement calls for Lilly to sell the ingredients needed to manufacture both human and analogue insulin at a “significantly reduced” price to EVA Pharma and also provide “pro bono” technology so that the Egyptian company can formulate, fill and finish insulin vials and cartridges. Distribution to 56 countries — all but a handful located in Africa — is expected to begin within 18 months.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
